PubMedReviewHuman Subjects

Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.

McCall Kenneth L, Mastro Dwyer Keri A, Casey Ryan T, Samana Tasnia N, Sulicz Ewa K, Tso Susannah Y, Yalanzhi Emma R, Piper Brian J

Expert opinion on drug safety2026DOI: 10.1080/14740338.2025.2499670

GLP-1 receptor agonistsliraglutidesemaglutidetirzepatide

Quality Score

6/10

Citations

Subjects

Human

Peptide Contacts Analysis

Study Design

Review papers serve a critical role in synthesizing disparate findings into a coherent narrative. For rapidly evolving fields like peptide therapeutics, reviews help researchers and practitioners identify consensus and controversy.

Our Assessment

Quality Assessment: 6/10 — This is a solidly conducted study with clear methodology and reasonable conclusions. Minor limitations exist (noted below) but don't undermine the core findings. The evidence here is reliable enough to inform both research direction and practical decision-making.

Findings in Context

These findings advance our understanding of GLP-1 receptor agonists, liraglutide, semaglutide, tirzepatide in meaningful ways. The human-subjects design makes these results particularly relevant for clinical translation.

On the Limitations

Every study has limitations, and being transparent about them is what separates good science from hype. These limitations don't invalidate the findings — they define the boundaries of what we can confidently conclude.

The Takeaway

Bottom line: Decent human data on GLP-1 receptor agonists, liraglutide, semaglutide, tirzepatide. Not the final word, but a meaningful data point that adds to the weight of evidence.

Key Findings

The study found that compounded GLP-1 receptor agonists had higher reporting odds ratios for adverse events such as abdominal pain, nausea, diarrhea, cholecystitis, and suicidality compared to non-compounded formulations. Additionally, compounded products were associated with a higher likelihood of medication errors and product quality issues.

Limitations

The study is based on retrospective analysis using the FDA Adverse Event Reporting System, which may introduce reporting biases. The lack of randomized controlled trials limits the ability to establish causality between compounded GLP-1 RAs and adverse events.

How to Interpret This Research

Look for the sample size — larger studies produce more reliable results. Single-digit sample sizes warrant caution.

Check whether the study was funded by a pharmaceutical company or conducted independently, as funding sources can influence study design and reporting.

Reviews are only as good as the studies they include. Check whether the review examined study quality or simply tallied results.

Look for discussion of publication bias — studies with negative results are less likely to be published, which can skew review conclusions.

Always consult a qualified healthcare provider before making treatment decisions based on research findings. Published research is not a substitute for personalized medical advice.

Peptide Contacts Analysis

Highlighting the risks associated with compounded GLP-1 receptor agonists and advocating for stringent safety standards.

GLP-1 receptor agonistsliraglutidesemaglutidetirzepatide

The Risks of Compounded GLP-1 Receptor Agonists: A Cautionary Tale

Published: May 16, 2026 | Source: Expert opinion on drug safety (2026) | Category: GLP-1 receptor agonists, liraglutide, semaglutide, tirzepatide

Overview

A recent study published in Expert Opinion on Drug Safety highlights the increased risks associated with compounded formulations of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), commonly used for diabetes and obesity management. The research underscores that these compounded drugs may pose higher safety concerns, including adverse events and medication errors, compared to FDA-approved products.

Study Background

Compounded GLP-1 RAs are not subject to the same rigorous testing as FDA-approved medications, raising questions about their safety and efficacy. This study aimed to evaluate the safety profile of compounded GLP-1 RAs by analyzing reports in the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) from 2018 to 2024.

What the Research Found

The retrospective analysis of FAERS data revealed that out of 81,078 GLP-1 RA safety reports, 707 involved compounded products. Compounded formulations were associated with higher reporting odds ratios (RORs) for several adverse events:

Abdominal pain: ROR = 2.84
Diarrhea: ROR = 1.59
Nausea: ROR = 1.27
Suicidality: ROR = 6.34
Cholecystitis: ROR = 3.39

Additionally, compounded GLP-1 RAs were linked to a higher likelihood of medication errors and product quality issues:

Preparation errors: ROR = 48.92
Prescribing errors: ROR = 4.46
Contamination: ROR = 19.00
Compounding/manufacturing issues: ROR = 8.51

These findings suggest that compounded GLP-1 RAs may carry a higher risk of adverse events and safety concerns compared to FDA-approved products.

What This Means for Peptide Users

The study's results indicate that patients using compounded GLP-1 RAs might face an elevated risk of experiencing adverse effects, including gastrointestinal issues and psychological distress. Healthcare providers should exercise caution when prescribing these compounds and ensure rigorous quality control measures are in place. Patients should be informed about the potential risks associated with compounded formulations and consider FDA-approved alternatives if available.

Limitations and Caveats

While this study provides valuable insights into the safety profile of compounded GLP-1 RAs, it is important to acknowledge its limitations:

Retrospective Analysis: The findings are based on retrospective data from FAERS, which may be subject to reporting biases.
Lack of Randomized Controlled Trials (RCTs): Without RCTs, the study cannot definitively establish causality between compounded GLP-1 RAs and adverse events.

How This Compares to Previous Research

Previous studies have also highlighted safety concerns associated with compounded medications. However, this is one of the first comprehensive analyses focusing specifically on GLP-1 RAs. The findings align with broader literature suggesting that compounded drugs may pose unique risks due to variations in manufacturing processes and quality control.

Our Analysis

PeptideVault's analysis underscores the importance of this study for both healthcare providers and patients. While compounded medications can offer flexibility in treatment options, especially for rare conditions or personalized dosing requirements, the increased risk profile highlighted by this research should prompt a reevaluation of their use. The findings reinforce the need for stringent safety standards and enhanced monitoring mechanisms to protect patient health.

Key Takeaways

Higher Risk Profile: Compounded GLP-1 RAs are associated with higher odds of adverse events compared to FDA-approved products.
Quality Control Issues: These compounded drugs face a greater likelihood of preparation, prescribing, contamination, and manufacturing errors.
Patient Monitoring: Healthcare providers should closely monitor patients using compounded GLP-1 RAs for potential adverse effects.

Original Source

Citation: McCall Kenneth L, Mastro Dwyer Keri A, Casey Ryan T et al. (2026). Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.. Expert opinion on drug safety. DOI: 10.1080/14740338.2025.2499670

Access: https://pubmed.ncbi.nlm.nih.gov/40285721/

---

This article is for informational and research purposes only. PeptideVault summarizes and analyzes published research. Always consult a licensed healthcare provider.

Editor's Note

This analysis was written by the Peptide Contacts research team to make complex findings accessible to the peptide community. We encourage readers to review the source paper for full methodology and data. For more on GLP-1 receptor agonists, explore our research guides.

Citation

McCall Kenneth L, Mastro Dwyer Keri A, Casey Ryan T et al.. (2026). Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.. Expert opinion on drug safety. https://doi.org/10.1080/14740338.2025.2499670

View full text on PubMed

Related Papers

Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.

Sinha Binayak et al.· Obesity (Silver Spring, Md.)· 2025Meta-Analysis

Medications for Obesity: A Review.

Gudzune Kimberly A et al.· JAMA· 2024Meta-Analysis

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.

Rosenstock Julio et al.· Lancet (London, England)· 2021Randomized Controlled Trial

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.

Rubino Domenica et al.· JAMA· 2021Randomized Controlled Trial

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.

Rubino Domenica M et al.· JAMA· 2022Randomized Controlled Trial

Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes.

Silver Heidi J et al.· Diabetes, obesity & metabolism· 2023Randomized Controlled Trial

Explore Further

Research Library

Browse all indexed papers

Research Guides

Plain-language peptide guides

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.